Physician profile
Mohammad Ashfaq
NPI 1790726420
$15,074.46
in general payments reported to CMS, 2019-2025
18 companies · $6,837 in 2025
The $6,837 reported for 2025 was more than what 92% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $553 · 2020: $363 · 2021: $2,518 · 2022: $325 · 2023: $819 · 2024: $3,659 · 2025: $6,837.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,125 · Food and Beverage: $3,134 · Travel and Lodging: $1,057.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,125.00 |
| Food and Beverage | $3,133.50 |
| Travel and Lodging | $1,056.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $10,064.18 | 2019-2025 | Mavyret |
| Gilead Sciences, INC. | $3,595.37 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $355.35 | 2019-2025 | Ocaliva |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $283.31 | 2020-2025 | Xifaxan |
| Madrigal Pharmaceuticals | $241.71 | 2024-2025 | Resmetirom, Rezdiffra |
| Shionogi INC | $160.36 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $85.30 | 2022-2025 | Terlivaz |
| Novo Nordisk INC | $49.04 | 2025 | Wegovy |
| Eisai INC. | $48.01 | 2024 | |
| Alexion Pharmaceuticals, INC. | $44.45 | 2019 | |
| Vifor Pharma, INC. | $21.50 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $21.49 | 2024 | Iqirvo |
| Mirum Pharmaceuticals, INC. | $20.66 | 2025 | Chenodal, Cholbam, Livmarli |
| Boston Scientific Corporation | $19.44 | 2024 | Varithena Administration Pack |
| Nestle Healthcare Nutrition INC. | $18.01 | 2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dova Pharmaceuticals | $16.90 | 2020 | |
| Dynavax Technologies Corporation | $15.98 | 2020 | |
| Merck Sharp & Dohme LLC | $13.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Ashfaq listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.